CYDUCT reports early microfluidic pad results for nipple aspirate fluid testing

CYDUCT Diagnostics said a pilot study found its microfluidic pad could preserve microRNA biomarkers in nipple aspirate fluid for up to seven days at room temperature, a step that could simplify breast ductal biomarker collection and transport. The company said the early data support further development, though larger studies are still needed.

Why it matters: - CYDUCT Diagnostics is trying to make breast duct biomarker testing easier to collect, store and move. - The early results suggest the company’s pad could support more practical breast health screening workflows if later studies confirm the findings. - The technology is aimed at earlier detection and more precise breast health management.

What happened: - CYDUCT Diagnostics announced preliminary results from a pilot study of its proprietary microfluidic pad for collecting and preserving nipple aspirate fluid for microRNA testing. - The study found microRNA biomarkers remained extractable and detectable after storage on the pad for up to seven days at room temperature. - Analytical quality stayed comparable to the standard laboratory method across the storage intervals tested. - The company is based in Westport, Connecticut.

The details: - Biomarker recovery on the pad was lower than with the standard protocol. - All samples remained within the analytical detection range. - The company said further optimization may improve recovery. - CYDUCT described the platform as a simpler, more practical and flexible way to collect, handle and transport breast ductal biomarkers. - More product information will be posted on the company website at the company's website.

Between the lines: - The announcement is encouraging, but the dataset is still early and limited to a pilot study. - The fact that recovery lagged the standard method shows the product still has technical work ahead before it can be judged against existing lab processes. - CYDUCT is positioning the pad as a workflow tool, not just a lab test input, which could matter if transport and storage are major barriers in breast biomarker testing.

What's next: - Larger, replicated studies are needed to confirm the pilot results. - CYDUCT said continued development will focus on improving the platform’s performance. - Investors and clinicians will likely look for more data on recovery rates, reproducibility and real-world usability.

The bottom line: - CYDUCT has an early signal that its microfluidic pad can preserve key breast biomarker material under simple storage conditions, but the technology still needs stronger validation before it can move beyond promising preliminary data.